Previous close | 28.80 |
Open | 20.70 |
Bid | 20.60 |
Ask | 21.30 |
Strike | 130.00 |
Expiry date | 2025-01-17 |
Day's range | 19.70 - 20.70 |
Contract range | N/A |
Volume | |
Open interest | 1.9k |
Pharmaceutical stocks Novo Nordisk (NVO) and Moderna (MRNA) are trending in opposite directions following their earnings reports. Despite topping Wall Street's profit expectations, Novo Nordisk shares are sinking as the company fell short of estimates for its popular GLP-1 weight-loss drug, Wegovy. Meanwhile, Moderna is on the rise even after reporting first quarter losses. Moderna's growth is largely due to an uptick in coronavirus boosters and an expansion into the Brazillian market. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This post was written by Melanie Riehl
Moderna stock broke out for the first time in a year Thursday after beating first-quarter expectations as its second potential approval looms.
Thursday, Moderna Inc (NASDAQ:MRNA) reported a first-quarter EPS loss of $(3.07), down from an income of $(0.19), smaller than the consensus estimate loss of $(3.55). The company reported sales of $167 million, sharply below $1.9 billion a year ago due to evaporating COVID-19 vaccine sales, beating the consensus of $97.5 million. The company cut research and development expenses by 6% in the quarter, mainly due to the absence of upfront collaboration payments. Moderna added that clinical develop